Secretome and extracellular vesicle signatures in bone marrow-derived mesenchymal stromal cells after expansion in standard and next-generation media

Abstract

Aim: Mesenchymal stem cells (MSCs) are a promising therapeutic strategy for osteoarthritis (OA), largely due to their regenerative potential, which is attributed in part to their secretome. The secretome includes soluble factors and extracellular vesicles (EVs). Given that MSCs are sensitive to various culture conditions, this study aims to investigate the effects of different media supplemented with either fetal bovine serum (FBS) (F), platelet lysate (P), or serum/xeno-free (S/X) on the composition and therapeutic potential of the secretome from bone marrow-derived MSCs (BMSCs).

Methods: BMSCs were cultured in F, P, or S/X media, with secretomes collected after starvation. The secretomes were analyzed for soluble factors, EVs, and miRNAs. Inflammatory responses were assessed in an in vitro OA model using inflamed chondrocytes and gene expression was evaluated by qRT-PCR.

Results: The secretomes from all conditions exhibited a similar molecular fingerprint. Proteomic analysis identified 98 common proteins encompassing growth factors and inflammatory mediators. EVs showed similar size and phenotype, with a slight difference in CD44 expression in EVs derived from P-expanded MSCs. Despite the high overall similarity, miRNA profiling identified 13 key players, with subtle differences in the miRNA composition of EVs from FBS-expanded BMSCs. All secretomes exhibited anti-inflammatory effects, with the FBS-expanded secretome showing the most pronounced therapeutic potential.

Conclusion: The secretomes derived from different culture conditions share key molecular components. EVs may contribute to variations in therapeutic outcomes through their cargo. Optimizing MSC expansion conditions is crucial for enhancing the therapeutic potential of MSC-derived secretomes in OA treatment. Further research is needed to clarify the specific role of factors, miRNAs, and EVs in modulating OA pathology.

Keywords

Mesenchymal stromal cells / secretome / extracellular vesicles / miRNA / orthopedics / osteoarthritis

References

[1] Mavrogenis AF,Zikopoulos A.Orthobiologics: a review.Int Orthop2023;47:1645-62

[2] Laver L, Filardo G, Sanchez M, et al; ESSKA‐ORBIT Group. The use of injectable orthobiologics for knee osteoarthritis: a European ESSKA-ORBIT consensus. Part 1-Blood-derived products (platelet-rich plasma). Knee Surg Sports Traumatol Arthrosc. 2024;32:783-97.

[3] Perucca Orfei C,Sourugeon Y.Cell-based therapies have disease-modifying effects on osteoarthritis in animal models. A systematic review by the ESSKA orthobiologic initiative. Part 1: adipose tissue-derived cell-based injectable therapies.Knee Surg Sports Traumatol Arthrosc2023;31:641-55 PMCID:PMC9898370

[4] Boffa A,Sourugeon Y.Cell-based therapies have disease-modifying effects on osteoarthritis in animal models. A systematic review by the ESSKA orthobiologic initiative. Part 2: bone marrow-derived cell-based injectable therapies.Knee Surg Sports Traumatol Arthrosc2023;31:3230-42 PMCID:PMC10356673

[5] Boffa A,Merli G.Platelet-rich plasma injections induce disease-modifying effects in the treatment of osteoarthritis in animal models.Knee Surg Sports Traumatol Arthrosc2021;29:4100-21

[6] Rodeo SA.Orthobiologics: current status in 2023 and future outlook.J Am Acad Orthop Surg2023;31:604-13

[7] The use of injectable Orthobiologics for knee osteoarthritis: a formal ESSKA consensus Part 2 - cell-based therapy (CBT). Available from: https://cdn.ymaws.com/www.esska.org/resource/resmgr/docs/consensus_projects/2024_orbit_complete_report.pdf. [Last accessed on 24 Apr 2025].

[8] Caplan AI.The MSC: an injury drugstore.Cell Stem Cell2011;9:11-5 PMCID:PMC3144500

[9] Caplan AI.Mesenchymal stem cells: time to change the name!.Stem Cells Transl Med2017;6:1445-51 PMCID:PMC5689741

[10] Miclau K,Huard J,Bahney CS.Cellular expansion of MSCs: shifting the regenerative potential.Aging Cell2023;22:e13759 PMCID:PMC9835588

[11] Harrison-Brown M,Hafsi K.Efficacy and safety of culture-expanded, mesenchymal stem/stromal cells for the treatment of knee osteoarthritis: a systematic review protocol.J Orthop Surg Res2019;14:34 PMCID:PMC6347797

[12] Ragni E,De Luca P.Inflammatory priming enhances mesenchymal stromal cell secretome potential as a clinical product for regenerative medicine approaches through secreted factors and EV-miRNAs: the example of joint disease.Stem Cell Res Ther2020;11:165 PMCID:PMC7189600

[13] Ragni E,de Girolamo L.Secreted factors and extracellular vesicles account for the immunomodulatory and tissue regenerative properties of bone-marrow-derived mesenchymal stromal cells for osteoarthritis.Cells2022;11:3501 PMCID:PMC9658264

[14] Gstraunthaler G,van der Valk J.A plea to reduce or replace fetal bovine serum in cell culture media.Cytotechnology2013;65:791-3 PMCID:PMC3967615

[15] Rowland AL,Levine GJ.Preparation technique affects recipient immune targeting of autologous mesenchymal stem cells.Front Vet Sci2021;8:724041 PMCID:PMC8478329

[16] Iudicone P,Bonanno G.Pathogen-free, plasma-poor platelet lysate and expansion of human mesenchymal stem cells.J Transl Med2014;12:28 PMCID:PMC3918216

[17] Aussel C,Vantomme H,Martinaud C.Quality assessment of a serum and xenofree medium for the expansion of human GMP-grade mesenchymal stromal cells.PeerJ2022;10:e13391 PMCID:PMC9161815

[18] Bui HTH,Than UTT.Influences of Xeno-free media on mesenchymal stem cell expansion for clinical application.Tissue Eng Regen Med2021;18:15-23 PMCID:PMC7862486

[19] Dominici M,Mueller I.Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement.Cytotherapy2006;8:315-7

[20] Fitzgerald JC,Murphy JM.Media matters: culture medium-dependent hypervariable phenotype of mesenchymal stromal cells.Stem Cell Res Ther2023;14:363 PMCID:PMC10717324

[21] Liu S,Jin P.Manufacturing differences affect human bone marrow stromal cell characteristics and function: comparison of production methods and products from multiple centers.Sci Rep2017;7:46731 PMCID:PMC5406832

[22] Giannasi C,Cadelano F.Boosting the therapeutic potential of cell secretome against osteoarthritis: comparison of cytokine-based priming strategies.Biomed Pharmacother2024;170:115970

[23] Ragni E,Viganò M.Cartilage protective and immunomodulatory features of osteoarthritis synovial fluid-treated adipose-derived mesenchymal stem cells secreted factors and extracellular vesicles-embedded miRNAs.Cells2021;10:1072 PMCID:PMC8147187

[24] D’haene B,Hellemans J.miRNA expression profiling: from reference genes to global mean normalization.Methods Mol Biol.2012;822:261-72

[25] Szklarczyk D,Koutrouli M.The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest.Nucleic Acids Res2023;51:D638-46 PMCID:PMC9825434

[26] Metsalu T.ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap.Nucleic Acids Res2015;43:W566-70 PMCID:PMC4489295

[27] Lipps C,Wahlicht T.Expansion of functional personalized cells with specific transgene combinations.Nat Commun2018;9:994 PMCID:PMC5843645

[28] Chou CH,Gibson J.Synovial cell cross-talk with cartilage plays a major role in the pathogenesis of osteoarthritis.Sci Rep2020;10:10868 PMCID:PMC7331607

[29] Chouaib B,Cuisinier F.Dental pulp stem cell conditioned medium enhance osteoblastic differentiation and bone regeneration.Stem Cell Rev Rep2025;21:477-90

[30] Su Y,Cheng W,Sui L.Pretreated mesenchymal stem cells and their secretome: enhanced immunotherapeutic strategies.Int J Mol Sci2023;24:1277 PMCID:PMC9864323

[31] Bowles AC,Willman MA,Agarwal A.Signature quality attributes of CD146⁺ mesenchymal stem/stromal cells correlate with high therapeutic and secretory potency.Stem Cells2020;38:1034-49

[32] Cheng NC,Lee NH.Influence of human platelet lysate on extracellular matrix deposition and cellular characteristics in adipose-derived stem cell sheets.Front Cell Dev Biol2020;8:558354 PMCID:PMC7642065

[33] Gharibi B.Effects of medium supplements on proliferation, differentiation potential, and in vitro expansion of mesenchymal stem cells.Stem Cells Transl Med2012;1:771-82 PMCID:PMC3659663

[34] Civinini R,Martini C,Ristori G.Growth factors in the treatment of early osteoarthritis.Clin Cases Miner Bone Metab2013;10:26-9 PMCID:PMC3710006

[35] Wen C,Xu X,Liang Y.Insulin-like growth factor-1 in articular cartilage repair for osteoarthritis treatment.Arthritis Res Ther2021;23:277 PMCID:PMC8556920

[36] Su S,Roughley PJ.Expression of the tissue inhibitor of metalloproteinases (TIMP) gene family in normal and osteoarthritic joints.Rheumatol Int1999;18:183-91

[37] Deng ZH,Gao X,Huard J.Bone morphogenetic proteins for articular cartilage regeneration.Osteoarthritis Cartilage2018;26:1153-61

[38] Luo W,Yuan Y,Zhong W.Osteopontin (OPN) alleviates the progression of osteoarthritis by promoting the anabolism of chondrocytes.Genes Dis2023;10:1714-25 PMCID:PMC10311054

[39] Tat SK,Velasco CR,Martel-Pelletier J.New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target?.Keio J Med2009;58:29-40

[40] Di Cicco G,Mastrostefano A.The pathogenetic role of RANK/RANKL/OPG signaling in osteoarthritis and related targeted therapies.Biomedicines2024;12:2292 PMCID:PMC11505501

[41] Zhu R,Wang J.Inflammation as a therapeutic target for osteoarthritis: a literature review of clinical trials.Clin Rheumatol2024;43:2417-33 PMCID:PMC11269414

[42] Harrell CR,Djonov V,Volarevic V.Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases.Cells2019;8:1605 PMCID:PMC6952783

[43] You B,Yang Y.MSC-EVs alleviate osteoarthritis by regulating microenvironmental cells in the articular cavity and maintaining cartilage matrix homeostasis.Ageing Res Rev2023;85:101864

[44] Zhou L,Sugita S.Role of CD44 in increasing the potency of mesenchymal stem cell extracellular vesicles by hyaluronic acid in severe pneumonia.Stem Cell Res Ther2021;12:293 PMCID:PMC8136222

[45] Jones M,Kouroupis D.The use of mesenchymal stem/stromal cell-derived extracellular vesicles in the treatment of osteoarthritis: insights from preclinical studies.Bioengineering2024;11:961 PMCID:PMC11504680

[46] Nejad C,Gantier MP.A guide to miRNAs in inflammation and innate immune responses.FEBS J2018;285:3695-716

[47] Song J,Kim D,Chun CH.MicroRNA-222 regulates MMP-13 via targeting HDAC-4 during osteoarthritis pathogenesis.BBA Clin2015;3:79-89 PMCID:PMC4661531

[48] Liu H,Huang Y.Macrophage-derived mir-100-5p orchestrates synovial proliferation and inflammation in rheumatoid arthritis through mTOR signaling.J Nanobiotechnology2024;22:197 PMCID:PMC11034106

[49] Graff JW,Clay G,Wilson ME.Identifying functional microRNAs in macrophages with polarized phenotypes.J Biol Chem2012;287:21816-25 PMCID:PMC3381144

[50] Meng F,Zhang Z.MicroRNA-193b-3p regulates chondrogenesis and chondrocyte metabolism by targeting HDAC3.Theranostics2018;8:2862-83 PMCID:PMC5957014

[51] Wu J,Chen C.miR-100-5p-abundant exosomes derived from infrapatellar fat pad MSCs protect articular cartilage and ameliorate gait abnormalities via inhibition of mTOR in osteoarthritis.Biomaterials2019;206:87-100